ESSENTIAL MESSAGES FROM ESC GUIDELINES

Committee for Practice Guidelines
To improve the quality of clinical practice and patient care in Europe

AFib

GUIDELINES FOR THE MANAGEMENT OF ATRIAL FIBRILLATION

For more information www.escardio.org/guidelines
ESC ESSENTIAL MESSAGES

2016 ESC GUIDELINES FOR THE MANAGEMENT OF ATRIAL FIBRILLATION*

The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).

Developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS), and with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC

Endorsed by the European Stroke Organisation (ESO)

Chairperson
Paulus Kirchhof
Institute of Cardiovascular Sciences
University of Birmingham
IBR - Wolfson Drive
Birmingham B15 2TT, United Kingdom
Tel: +44 121 4147042
Email: p.kirchhof@bham.ac.uk

Co-Chairperson
Stefano Benussi
Department of Cardiovascular Surgery
University Hospital Zurich
Rämistrasse 100
8091 Zürich, Switzerland
Tel: +41 (0)7 88 93 38 35
Email: stefano.benussi@usz.ch

Task Force Members:
Dipak Kotecha (UK), Anders Ahlsson (Sweden), Dan Atar (Norway), Barbara Casadei (UK), Manuel Castella Pericas (Spain), Hans-Christoph Diener (Germany), Hein Heidbuchel (Belgium), Jeroen Hendriks (The Netherlands), Gerhard Hindricks (Germany), Antonis S. Manolis (Greece), Jonas Oldgren (Sweden), Bogdan Alexandru Popescu (Romania), Ulrich Schotten (The Netherlands), Bart Van Putte (The Netherlands), Panagiotis Vardas (Greece)

Other ESC entities having participated in the development of this document:
Associations: European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), Heart Failure Association (HFA).
Councils: Council on Cardiovascular Nursing and Allied Professions.
Working Groups: Cardiac Cellular Electrophysiology, Cardiovascular Pharmacotherapy.

Special thanks to Dipak Kotecha for his contribution.

ESC Staff:
Veronica Dean, Catherine Despres, Maike Binet – Sophia Antipolis, France

Table of contents

- Section 1 - Take home messages
- Section 2 - Major gaps in evidence
1. **Atrial fibrillation (AF) is:**
   - The most common heart rhythm disorder, with a steep rise predicted in the number of patients in coming years.
   - One of the major causes of stroke, heart failure, sudden death, and cardiovascular morbidity.
   - Associated with poorer quality of life and symptoms including lethargy, palpitations, breathlessness, chest tightness, sleeping difficulties, and psychosocial distress.

2. **Diagnosis & screening:**
   - The diagnosis of AF requires an electrocardiogram (ECG) showing irregular RR intervals and no distinct P waves for at least 30 seconds.
   - ECG screening is useful in populations at risk of AF or those at high risk of stroke, including stroke survivors and older patients.

3. **Prevention & general management:**
   - Treat underlying cardiovascular conditions adequately to prevent AF, such as hypertension, ischaemia, valvular heart disease and heart failure.
   - Evaluate AF-related symptoms using the modified European Heart Rhythm Association (EHRA) score.

---

**Take home messages**

**ESSENTIAL MESSAGES FROM THE 2016 ESC GUIDELINES FOR THE MANAGEMENT OF ATRIAL FIBRILLATION**

- **Acute rate and rhythm control**
- **Manage precipitating factors**
- **Assess stroke risk**
- **Assess heart rate**
- **Assess symptoms**
- **Lifestyle changes, treatment of underlying cardiovascular conditions**
- **Oral anticoagulation in patients at risk for stroke**
- **Rate control therapy**
- **Antiarrhythmic drugs, cardioversion, catheter ablation, AF surgery**

**Treatment**

- **Chronic management**
  - Haemodynamic stability
  - Cardiovascular risk reduction
  - Stroke prevention
  - Symptom improvement, preservation of LV function
  - Symptom improvement

**Desired outcome**

**Patient benefit**

- Improved life expectancy
- Improved quality of life, autonomy, social functioning
4. Patient involvement:
- Provide tailored information and education to AF patients to empower them to support the management of their condition.
- Propose lifestyle changes to all suitable AF patients to make their management more effective.

5. Stroke prevention:
- Use oral anticoagulation in all AF patients unless they are at low risk for stroke based on the CHA₂DS₂-VASc score, or have absolute contraindications for anticoagulant therapy.
- When initiating anticoagulation, a non-vitamin K antagonist oral (NOAC) is preferred, except in patients with moderate-to-severe mitral stenosis, mechanical heart valves or severe kidney disease.
- Anticoagulate patients with atrial flutter similar to atrial fibrillation.
- Reduce modifiable bleeding risk factors in all AF patients on oral anticoagulation, e.g. by treating hypertension, minimising the use of antiplatelets and NSAIDs, treating anaemia, eliminating causes for blood loss, maintaining stable INR values in patients on vitamin K antagonists, and moderating alcohol intake.
- Do not use aspirin or other antiplatelets for stroke prevention in AF.

6. Heart rate control:
- Check ventricular rate in all AF patients and use rate control medications to achieve lenient rate control (<110 bpm at rest).
- Use increased dosage or additional rate control therapy in patients that continue to have symptoms due to AF.
- Assessment of cardiac function (e.g. using echocardiography) can guide the choice of appropriate rate control therapy.
7. Rhythm control:

- Restoring and maintaining sinus rhythm is aimed at improving AF-related symptoms in suitable patients.
- Do not use rhythm control therapy in asymptomatic AF patients, or those with permanent AF.

a. Acute rhythm control

- Electrical and pharmacological cardioversion can be used to restore sinus rhythm in selected patients, after considering and managing the risk of stroke.

b. Anti-arrhythmic drugs

- Select anti-arrhythmic drugs based on their safety profile.
- Use shorter duration of therapy where possible, and combine with weight reduction, blood pressure control, heart failure treatment and moderate exercise to reduce AF burden.

c. Catheter ablation

- Consider catheter ablation (pulmonary vein isolation) when antiarrhythmic drugs fail, or in selected patients as first-line therapy for symptomatic paroxysmal AF.
- Anticoagulation for stroke prevention should be continued indefinitely in patients at high risk of stroke, even after apparently successful ablation of AF.

d. Surgical AF ablation

- Ablation can be performed in symptomatic patients during cardiac surgery for other reasons, or by stand-alone surgery either using open-chest techniques or by thoracoscopy.
- Anticoagulation for stroke prevention should be continued indefinitely in patients at high risk of stroke, even after apparently successful ablation of AF.

8. Integrated care & the AF Heart Team approach

- An integrated, structured approach to AF care is recommended to facilitate consistent, guideline-adherent AF management for all patients, with the potential to improve outcomes.
- Integrated care includes a multidisciplinary approach with cooperation of nurses specialising in AF, primary care physicians, cardiologists, stroke specialists, allied health practitioners and informed patients.
- For complex and difficult decisions, particularly for patients after failed rhythm control, an AF Heart Team should advise future management, consisting of a cardiologist, interventional electrophysiologist and cardiac surgeon, all with experience in managing AF.
Major gaps in evidence

1. Phenotypes of AF
   Atrial fibrillation has different causes in different patients. More research is needed to identify and treat distinct types of AF.

2. How much AF constitutes a mandate for therapy?
   Adequately powered studies are required to evaluate the diagnostic accuracy of new technologies for screening AF, the diagnostic yield in different populations, and the implications on anticoagulant and other therapy.

3. Stroke risk in specific populations
   Specific AF groups should be studied to better characterize their risk for AF, stroke, and other complications, including patients with one stroke risk factor, women and non-Caucasian patients.

4. Anticoagulation
   a. After ‘successful’ rhythm control:
      Currently, anticoagulation should be continued in AF patients at risk of stroke, even after successful restoration of sinus rhythm. Controlled trials are required to evaluate the safety and timing of termination of anticoagulation in these patients.
   b. For cardioversion:
      Oral anticoagulation is recommended for cardioversion of new-onset AF over 48 hours, but safety may be further improved by initiating pre-cardioversion anticoagulation at <24 hours.
   c. In patients with chronic kidney disease:
      There is very little evidence on the effects of anticoagulation in patients with GFR <30 mL/min, or on renal replacement therapy, groups at high risk of both stroke and bleeding.
   d. After a bleed or stroke:
      Even after major or intracranial bleeding, reinitiating anticoagulation may still have a net clinical benefit. Patients with a prior ischaemic stroke are at the highest risk of recurrent events.

5. Left atrial appendage (LAA) occlusion for stroke prevention
   LAA occluders have yet to be tested against NOACs, or for the most common clinical indication, patients with absolute contraindication for oral anticoagulation.

6. Comparison of rate control agents
   Rate control is almost universally used but there is very limited evidence comparing the effects of different agents.

7. Key questions on catheter ablation
   Can rhythm control therapy convey a prognostic benefit in AF? How effective is ablation in persistent and long-standing persistent AF? What is the optimal technique for repeat catheter ablation?

8. Key questions on surgical AF ablation
   What are the benefits and risks of thoracoscopic AF ablation? Does surgical LAA exclusion prevent strokes in AF? What lesion sets and energy sources should be used in concomitant AF surgery?
COMING SOON - Two NEW AF Apps
Better Integrated Care of your Patients

Revolutionize your clinical decision-making and patient management with two new AF management Apps - one for you and one for your patients.

The **AF Manager App**, for healthcare professionals, and the **My AF App**, for patients, have been developed to provide improved continuity of care, documentation of treatment and patient empowerment.

Download them SOON, free of charge, from the Google Play, Amazon and Apple App Stores.